Minze Health raises USD 5.3 million in funding to develop prescription digital therapeutics

image credit- shutterstock

Belgium-based company Minze Health, a pioneer in digital health solutions for urology, has successfully secured USD 5.3 million in a funding round led by its existing investors White Fund, Capricorn Digital Growth Fund, and the Flemish investment company PMV. The funding round also saw the participation of a new investor, imec.istart future fund.

The proceeds will be used to further develop and bring to market Prescription Digital Therapeutics (PDTs) for patients with urinary dysfunctions with an initial focus on Germany and France, as well as to drive US market entry with Minze’s at home diagnostic solutions.

Minze Health’s solutions for patients with urinary dysfunction and incontinence have been used by over 160.000 patients worldwide and are trusted by clinicians in 20+ countries. With a range of Digital Diagnostics, Remote Patient Monitoring and Digital Therapeutics products, Minze Health is the leading digital health player in the urology market.

The proceeds of the funding round will be utilized to drive utilization of Minze Health’s Homeflow and Diary Pod products in the US. Homeflow is an at-home uroflowmetry system of which the use can be charged under recently introduced Category III CPT billing codes. These reimbursement codes offer a significant opportunity to serve patients with benign prostatic hyperplasia (BPH) and similar conditions. Home uroflowmetry provides substantial benefits for managing BPH, which affects over 14 million men in the United States. By enabling patients to monitor urinary flow at home, this non-invasive solution gives clinicians continuous data to develop personalized treatment plans. It reduces the need for frequent clinic visits and empowers patients to manage their symptoms more effectively, allowing for earlier detection and timely interventions.